ロード中...
Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation
Although dual EGFR/HER2 tyrosine kinase inhibitor lapatinib has provided effective clinical benefits for HER2-positive breast cancer patients, acquired resistance to this drug remains a major concern. Thus, the development of alternative therapeutic strategies is urgently needed for patients who fai...
保存先:
| 出版年: | Int J Mol Sci |
|---|---|
| 主要な著者: | , , , , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
MDPI
2019
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6801459/ https://ncbi.nlm.nih.gov/pubmed/31569723 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/ijms20194812 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|